Vascular Dynamics Announces FDA Approval to Initiate CALM 2 Trial for MobiusHD® System for the Treatment of Resistant Hypertension
MOUNTAIN VIEW, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc., (VDI) a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to initiate its pivotal trial for its MobiusHD® System for the treatment of resistant hypertension.
The CALM (Controlling and Lowering Blood Pressure with MobiusHD) 2 trial is a multi-center, prospective, randomized, double-blind, sham-controlled pivotal study designed to evaluate the safety and effectiveness of the MobiusHD System. The company will evaluate patients from select locations throughout the United States whose hypertension remains uncontrolled despite using three or more anti-hypertensive pharmacologic therapies. VDI also intends to conduct the CALM 2 trial in certain European countries following appropriate regulatory authorization.
"The rigor and scientific focus of the Calm 2 trial has been crafted and improved from much of what we learned from prior studies. Calm 2 will offer patients a therapeutic alternative and a level of medical monitoring to which they otherwise would never have access outside of a clinical trial," said Bryan Williams co-Principal Investigator of the Calm 2 trial and Chair of Medicine at University College London and Director of the NIHR UCLH/UCL Biomedical Research Centre and Director of Research at UCL Hospitals. He is Chairman-Elect of the European Council on Hypertension of the European Society of Cardiology.
"In clinical practice, we are regularly faced with those hypertension patients who simply do not respond to medication or lifestyle changes. Initiating this trial is an important step toward identifying additional viable treatments to help this large population of patients," said Gregg Stone, MD, Co-Principal Investigator of the CALM 2 trial and director of cardiovascular research and education for Columbia University Medical Center/New York-Presbyterian Hospital and co-director of medical research and education at the Cardiovascular Research Foundation.
The company has been chosen as a participant in the FDA's Expedited Access Pathway (EAP) program, a focused initiative to significantly accelerate access for US patients and their physicians to innovative medical treatments. VDI is also one of only nine companies chosen for the FDA's Early Feasibility Study Investigational Device Exemptions (IDE) Pilot Program, which enables companies to conduct smaller-scale studies under the guidance of the Agency in the United States in order to meet the requirements for an earlier pathway toward approval.
"Initiating the CALM 2 trial is an important milestone for Vascular Dynamics as it allows us the opportunity to demonstrate the potential utility of our technology in a significant patient population," said Robert Stern, president and CEO of Vascular Dynamics. "With our participation in both the EAP and IDE programs, we also have the unique opportunity to work closely with the FDA to ensure a more rapid start to the trial while still maintaining the high standards of safety, efficacy and scientific validity required by the program."
The MobiusHD System, a minimally-invasive system, capitalizes on the ability of the body's baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby increase the body's natural response to lower blood pressure through vasodilation.
About Resistant Hypertension
Hypertension, or elevated blood pressure, is a common medical condition that currently affects one billion people worldwide.1 If left untreated, hypertension can cause life-threatening problems, including heart attack, aneurysm, stroke or kidney failure. Patients with hypertension can often reduce their risk factors by making lifestyle changes such as losing weight, quitting smoking, and increased exercise. In cases with advanced hypertension, medical therapies may be prescribed. Resistant hypertension cannot be controlled with medical therapies. Patients experiencing resistant hypertension are at four times greater risk of cardiovascular events compared with hypertensive patients achieving blood pressure targets.2 The American Heart Association (AHA) estimates that high blood pressure costs the U.S. $46 billion each year, including the cost of healthcare services, medications to treat high blood pressure, and lost productivity.
About Vascular Dynamics, Inc.
Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. The device is covered by seven issued and pending U.S. and international patents. The MobiusHD system has received a CE Mark for the treatment of hypertension in the European Union. However, the MobiusHD system is not commercially available in the United States. More information is available at www.vasculardynamics.com.
CAUTION: In the United States, the MobiusHD Device is limited by law to investigational use only.
1 Kearney PM, et al. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217-23
2 Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18: 1422-8.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vascular Dynamics, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
BBVA Continental: the bank making waves in Peru24.1.2018 12:31 | Pressmeddelande
LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- BBVA Continental has picked up the 2017 award for 'Best Private Bank - Peru' in World Finance magazine's yearly line-up, which recognises those in the industry that are outperforming the rest and making astute business decisions in preparation for future trends. BBVA continental is the second largest bank in Peru, but is number one when it comes to the cost of risk, coverage ratio and non-performing loan ratio. It is currently seeing outstanding growth, with a year-on-year increase in performing loans of 2 percent and a 6.1 percent year-on-year increase in deposits. It has also invested heavily in a transformative digital strategy, thereby laying the foundations for further expansion in the future. A remarkable shift in the way that people carry out transactions illustrates the success of its transition towards digital platforms. In 2008, internet banking comprised just 18 percent of its transactions, but the latest results show that this has n
Block X Capital Corp. Announces Completion of Change of Business to Investment Issuer, Change of Name, Change of Management and Resumption of Trading24.1.2018 11:00 | Pressmeddelande
VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Block X Capital Corp. ("Block X" or the "Company") (CSE:BXXX) is pleased to announce that further to its press release on December 7, 2017, the Company has completed a change of business from a Mining Issuer to an Investment Issuer and has received approval from the Canadian Securities Exchange to resume trading. In connection with the change of business, the Company has changed its name to "Block X Capital Corp.". Trading of the Company's common shares will resume under the new name and under the new ticker symbol "BXXX" at market open on January 24, 2018. The Company will seek investment opportunities in early-stage to mid-level blockchain and emerging technology companies, and will leverage its extensive network of operators and global thought leaders to provide investors with unparalleled access to investments that are not normally accessible to the average retail investor. The Company is pleased to announce that it has
Dog Meat Free Indonesia : Sickening animal cruelty at Indonesia's "extreme" markets where dogs and cats are bludgeoned, blowtorched alive24.1.2018 09:30 | Pressmeddelande
Government urged to take immediate action to protect animals and public health LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- The Indonesian government is being urged to shut down the country's cruel live animal markets, where thousands of dogs and cats a week are bludgeoned in public, blowtorched whilst still alive, and butchered for eating. Campaigners from the Dog Meat-Free Indonesia coalition filmed at two of the most notorious of Indonesia's 200 live animal markets in North Sulawesi, "Tomohon Extreme Market" and Langowan Market, to expose the horrifying suffering routinely endured by animals. Live dogs and cats are seen trembling in cages as one by one they are beaten over the head, howling in pain. Lola Webber, Dog Meat-Free Indonesia campaign coordinator, said: " It was like walking through hell. The dogs huddled together in cages , trembling with fear as they watched others being killed around them , waiting their turn. The sight of absolute terror in their eyes, the thumping of the
Promethean Expands Educational Display Portfolio to Create Immersive Classroom Experiences24.1.2018 09:18 | Pressmeddelande
Seattle, Wash., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Promethean TM, a global education technology company, announced expansions to its interactive flat panel portfolio which includes the market-leading ActivPanel and ActivPanel i-Series. The ActivPanel continues to offer the industry's most natural writing experience using InGlassTM technology, enabling both teachers and students to collaborate in front of the class with ease. The ActivPanel i-Series is an essential interactive flat panel for customers looking to replace their projector-based systems with a long-term, reliable solution. "Educators want technology that works as they do - flexible and able to adapt to their teaching styles in any classroom setting," said Ravi Angadi, Chief Products and Strategy Officer, Promethean. "At Promethean, we strive to create a dynamic ecosystem to enhance teacher productivity, providing educators with the latest innovative education technologies that are intuitive and immersive. With access to an e
Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11 | Pressmeddelande
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec
CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31 | Pressmeddelande
Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum